<DOC>
	<DOCNO>NCT02403440</DOCNO>
	<brief_summary>The purpose study obtain information efficacy , safety Pharmacokinetics ( PK ) /Pharmacodynamics ( PD ) Hetrombopag 14 day Chinese patient chronic ITP .</brief_summary>
	<brief_title>A Study Hetrombopag Olamine Chronic Idiopathic Thrombocytopenic Purpura ( ITP ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Chronical ITP patient . 2 . The subject diagnose ITP bone marrow aspiration within 3 month enrollment screening period . And secondary immune thrombocytopenia ( e.g. , myelodysplastic syndrome , systemic lupus erythematosus , aplastic anemia ) exclude . 3 . Patients mean platelet count le 30,000/µL screening period . 4 . Patients receive chronic maintenance steroid therapy must receive stable dose least 1 month . 5 . Patients receive danazol , mycophenolate mofetil cyclosporine A must receive stable dose least 12 week . 6 . Normal PT/INR APTT . 1 . Any prior history arterial venous thrombosis ( stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis pulmonary embolism ) , AND ≥ two follow risk factor : hormone replacement therapy , systemic contraception ( contain estrogen ) , smoke , diabetes , hypercholesterolemia , medication hypertension , cancer , hereditary thrombophilic disorder ( e.g. , Factor V Leiden , ATIII deficiency , etc ) , family history arterial venous thrombosis . 2 . Preexisting cardiovascular disease ( congestive heart failure , New York Heart Association [ NYHA ] Grade III/IV ) , arrhythmia know increase risk thromboembolic event ( e.g . atrial fibrillation ) . 3 . Malignant disease 4 . Cancer treatment cytotoxic chemotherapy and/or radiotherapy . 5 . Patients one follow condition exclude : Treatment immunoglobulin within 1 week precede first dose study medication . Treatment splenectomy rituximab within 12 week precede first dose study medication . Treatment eltrombopag Nplate within 4 week precede first dose study medication . Treatment cyclophosphamide vinca alkaloid within 4 week precede first dose study medication . 6 . ALT &gt; 2×ULN，AST &gt; 2×ULN，Total Bilirubin &gt; 1.5×ULN，serum creatinine &gt; 1.2×ULN，Total albumin &lt; 0.9×LLN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>